BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
PAT after MI is Rs. 41 crore which is 162% increase
Morepen Laboratories approves hiving off of medical devices business
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
The biosimilar Ustekinumab has been developed and manufactured by the company
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The product will be marketed by Dr. Reddy's
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Subscribe To Our Newsletter & Stay Updated
